AOR
Archives of Ophthalmological Research

The Archives of Ophthalmological Research aims to publish issues related to publish articles of the highest scientific and clinical value at an international level, and accepts articles on these topics. The target audience of the journal included specialists and physicians working in ophthalmology, and other health professionals interested in these fields.

eISSN: 3023-6479
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
Current use of aflibercept 8 mg (eylea HD) in retinal diseases
Abstract
Aflibercept 8 mg (Eylea HD) has emerged as a pivotal agent in the treatment of retinal diseases and has begun to showcase its efficacy and innovation in the field of ophthalmology. This article delves into the current use of aflibercept 8 mg, exploring its applications, mechanisms of action, and impact on the treatment landscape for various retinal conditions. This review provides an overview of recent clinical studies and highlights the key findings and advancements associated with the use of 8 mg aflibercept.

Keywords : Aflibercept 2 mg, aflibercept 8 mg, eylea HD, pphthalmology, retina, vascular endothelial growth factor

Download Article


1. Hang A, Feldman S, Amin AP, Ochoa JAR, Park SS. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders.Pharmaceuticals. 2023;16(8):1140.
2. You QS, Gaber R, Meshi A, et al. High-dose high-frequency afliberceptfor recalcitrant neovascular age-related macular degeneration. Retina.2018;38(6):1156-1165.
3. Çıtırık M, İlhan Ç, Teke MY. Yaş tip (neovasküler) yaşa bağlı maküladejenerasyonunda aflibercept tedavisi ve tedavi algoritmaları. GüncelRetina. 2017;1(3):198-205.
4. Gupta A. Bench-to-Bedside Research in Ophthalmology. In: Sobti R,Ganju AK, eds. Biomedical Translational Research. Springer: 2022:67-124.
5. Wykoff CC, Brown DM, Reed K, et al. Effect of high-dose intravitrealaflibercept, 8 mg, in patients with neovascular age-related maculardegeneration: the phase 2 CANDELA randomized clinical trial. JAMAOphthalmol. 2023;141(9):834-842.
6. Lanzetta P. Intravitreal aflibercept injection 8 mg for nAMD: 48-week results from the phase 3 PULSAR trial. American Academy ofOphthalmology 2022 Annual Meeting, September 30-October 3, 2022.Accessed November29,2022. https://investor.regeneron.com/static-files/e3307e7d-d495-438c-b8bb-c62cdacdb375
7. Brown DM. Intravitreal aflibercept injection 8 mg for DME: 48-weekresults from the phase 2/3 PHOTON trial. American Academy ofOphthalmology 2022 Annual Meeting, September 30-October 3, 2022.Accessed November 29, 2022. https://investor.regeneron.com/static-files/da20405e-b843-402e-855b-d824a15dec60
8. U.S. National Library of Medicine. A study to learn how well a higheramount of aflibercept given as an injection into the eye works andhow safe it is in people with reduced vision due to swelling in themacula, central part of the retina caused by a blocked vein in theretina (macula edema secondary to retinal vein occlusion) (QUASAR).Clinicaltrials.gov identifier: NCT05850520. Updated December 28,2023. Accessed January 01, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT05850520
9. Nielsen JS, Roberts CL, Saggau DD, Alliman KJ. High-dose afliberceptfor neovascular AMD and DME in suboptimal responders to standard-dose aflibercept. J Vitreoretin Dis. 2023;7(2):116-124.
Article available in :
Volume 1, Issue 1, 2024
Page : 10-12
https://doi.org/10.51271/AOR-0003
Article Information
Received : 01 Oca 2024
Accepted : 21 Oca 2024
Published : 29 Oca 2024
Corresponding Author :

Mehmet Çıtırık: Department of Ophthalmology, Ankara Etlik City Hospital, Ankara, Turkiye

[email protected]
Citation : Çıtırık M. Current use of aflibercept 8 mg (Eylea HD) in retinal diseases. Arch Ophthalmol Res. 2024;1(1):10-12.

Read: 307
Cited: 0
Download : 263
_Footer